<DOC>
	<DOCNO>NCT01230125</DOCNO>
	<brief_summary>The objective clinical study compare safety efficacy Mapracorat Ophthalmic Suspension , 3 % vehicle treatment postoperative inflammation pain follow cataract surgery .</brief_summary>
	<brief_title>Mapracorat Ophthalmic Suspension Treatment Ocular Inflammation Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<criteria>Participants candidate routine , uncomplicated cataract surgery Participants , Investigator 's opinion , potential postoperative pinhole Snellen visual acuity ( VA ) least 20/200 study eye . Participants must willing wait undergo cataract surgery fellow eye study complete . Participants expect require concurrent ocular therapy ( either eye ) nonsteroidal antiinflammatory drug ( NSAIDs ) , mast cell stabilizer , antihistamine , decongestant . Participants expect require treatment systemic ocular ( either eye ) corticosteroid glucocorticoid . Participants expect require concurrent ocular therapy immunosuppressant ( eg , Restasis ) . Participants know hypersensitivity contraindication study drug ( ) component . Participants participate drug device clinical investigation within 30 day prior entry study and/or period study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>Pain</keyword>
	<keyword>Ocular surgery</keyword>
</DOC>